Stockscreener 앱 받기
157.59
1.40%
2.18
시장 영업 전:
157.86
0.27
+0.17%
Novartis Ag Adr 주식(NVS)의 최신 뉴스
Novartis consensus picture on SIX, analysts keep a neutral view on the stock - AD HOC NEWS
Novartis opens the week with a cautious sector backdrop, shares in focus alongside Roche - AD HOC NEWS
NOTA Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Novartis AG Sponsored ADR – MUN:NOTA - TradingView
Novartis oncology partnership with Antares, shares trade near analyst targets - AD HOC NEWS
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSC) - TradingView
NVS News | NOVARTIS AG-SPONSORED ADR (NYSE:NVS) - ChartMill
Novartis focuses on oncology pipeline, shares track SMI pharma peers - AD HOC NEWS
907122 Forecast — Price Target — Prediction for 2027 - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Actuals & Estimates (BCBA:NVSD) - TradingView
Novartis AG Unsponsored Brazilian Depositary Receipt Repr 0.1 ADR Actuals & Estimates (BMFBOVESPA:N1VS34) - TradingView
NVS/N Forecast — Price Target — Prediction for 2027 - TradingView
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal - Sahm
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure - Sahm
Novartis highlights pipeline progress, shares trade steadily on NYSE - AD HOC NEWS
Novartis AG Stock (NVS) Closed Up by 3.04% on Jun 23: What Signal Does It Send? - TradingKey
Novartis refines India unit strategy, shares in focus on SIX trading - AD HOC NEWS
Novartis strategy highlighted by remibrutinib and Sandoz spin-off, shares steady on SIX - AD HOC NEWS
Why I Think This Vanguard ETF Will Beat the S&P 500 Over the Next 10 Years - The Motley Fool
Why Novartis lets Cosentyx step beyond psoriasis in everyday care - AD HOC NEWS
NOVARTIS AG-SPONSORED ADR (NVS) Stock Chart - ChartMill
Cash flow from operating activities of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Enterprise value to EBITDA ratio of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs Income Statement – BCBA:NVS.CI - TradingView
Preferred dividends of Novartis AG ADR Cert Deposito Arg Repr 0.25 ADRs – BCBA:NVS.CI - TradingView
Novartis AG Stock (CH0012005267): Earnings in focus for US investors - AD HOC NEWS
Novartis AG Stock (CH0012005267): Analyst Targets and SMI Role Keep Shares in Focus - AD HOC NEWS
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study - TradingView
Novartis AG Stock (CH0012005267): In focus on a quiet Sunday session - AD HOC NEWS
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study - Sahm
Novartis AG Stock (NVS) Moved Down by 3.14% on Jun 1: Key Drivers Unveiled - TradingKey
Novartis AG stock (CH0012005267): Pluvicto data keep focus on Swiss blue-chip pharma - Ad-hoc-news.de
Novartis AG (ADR) stock (CH0012005267): steady trading ahead of next catalysts - AD HOC NEWS
Novartis AG stock (CH0012005267): shares little changed as investors digest Swiss pharma group’s s - AD HOC NEWS
Novartis AG stock (CH0012005267): focus on Sandoz spin-off and pipeline momentum - AD HOC NEWS
Novartis AG stock (CH0012005267): eyeing Sandoz spin-off and new drug approvals - AD HOC NEWS
Novartis AG stock (CH0012005267): new MS drug filing and Q1 momentum attract attention - AD HOC NEWS
1.35%
1.21%
자본화:
|
볼륨(24시간):